Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NY › Little Falls › NPI 1558321919
Hospital

Little Falls Hospital

Little Falls Hospital was paid $18.70M by Medicaid between Jan 2018 and Dec 2024, across 212 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.

33Billing provider infoLITTLE FALLS HOSPITAL
LITTLE FALLS, NY 13365
33aNPI1558321919assigned 03/27/2006
33bProvider typeCritical Access Hospital
28Total paid$18.70M
24GClaims276,751
24DCodes billed212
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Critical Access Hospital providers in New York

Rank by total paid#1 of 12
Median peer was paid$5.23M
This provider vs. median3.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018930$58K
20198,983$386K
202046,801$1.91M
202158,001$2.80M
202257,295$7.00M
202355,889$4.08M
2024incomplete48,852$2.46M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 19% 14,523 13,902 $3.63M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 8.1% 10,082 9,575 $1.51M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 7.7% 6,434 6,183 $1.45M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 6.6% 8,767 8,449 $1.24M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 5.5% 4,890 4,711 $1.03M
99282 Emergency department visit for the evaluation and management, low to moderate severity 4.9% 3,301 3,236 $908K
74177 Computed tomography, abdomen and pelvis; with contrast material 4.2% 1,938 1,897 $781K
80053 Comprehensive metabolic panel 4.0% 13,592 13,051 $748K
36415 Collection of venous blood by venipuncture 3.7% 13,177 12,130 $699K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 2.7% 2,943 2,889 $500K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.3% 5,320 1,568 $431K
96361 Intravenous infusion, hydration; each additional hour 2.2% 1,421 1,347 $407K
200 more codes
70450 Computed tomography, head or brain; without contrast material 1.9% 997 $350K
74176 Computed tomography, abdomen and pelvis; without contrast material 1.7% 800 $315K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years 1.5% 1,947 $288K
81025 1.4% 4,080 $258K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years 1.3% 1,805 $239K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1.3% 5,530 $239K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 1.1% 1,270 $207K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 1.1% 1,133 $206K
99215 Doctor's office visit, returning patient (complex) <1% 1,136 $169K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 2,175 $159K
80048 Basic metabolic panel (calcium, ionized) <1% 4,903 $159K
80061 Lipid panel <1% 6,484 $153K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 1,084 $141K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 3,280 $108K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 16,315 $103K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 428 $102K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 2,109 $99K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,307 $97K
90686 <1% 2,522 $88K
84443 Thyroid stimulating hormone (TSH) <1% 6,583 $78K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 429 $78K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 375 $71K
Q3014 Telehealth originating site facility fee <1% 1,226 $70K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 495 $70K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 998 $68K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 6,101 $57K
71046 Radiologic examination, chest; 2 views <1% 2,028 $51K
90715 <1% 1,303 $41K
94010 <1% 214 $38K
71045 Radiologic examination, chest; single view <1% 2,120 $37K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 2,289 $36K
83036 Hemoglobin; glycosylated (A1C) <1% 4,190 $35K
86850 <1% 803 $35K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 499 $34K
J1050 Injection, medroxyprogesterone acetate, 1 mg <1% 226 $33K
97162 <1% 234 $32K
84484 <1% 3,025 $32K
99406 <1% 741 $29K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 24 $29K
76830 Ultrasound, transvaginal <1% 443 $29K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 383 $29K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 3,853 $28K
90375 <1% 12 $28K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 3,539 $24K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 102 $24K
83690 <1% 4,660 $24K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 321 $23K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 998 $20K
84439 <1% 1,888 $20K
82607 <1% 1,632 $19K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 535 $19K
77063 Screening digital breast tomosynthesis, bilateral <1% 1,166 $19K
73564 <1% 570 $19K
83735 <1% 4,161 $17K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 344 $17K
81001 <1% 4,655 $16K
A9585 Injection, gadobutrol, 0.1 ml <1% 425 $15K
71271 <1% 130 $15K
73610 <1% 721 $14K
G0444 Annual depression screening, 5 to 15 minutes <1% 343 $14K
87634 <1% 578 $14K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 142 $14K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 36 $14K
85027 <1% 2,047 $13K
71275 Computed tomographic angiography, chest, with contrast material <1% 43 $13K
96375 Therapeutic injection; each additional sequential IV push <1% 2,515 $13K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 24 $12K
80051 <1% 567 $12K
73630 <1% 723 $12K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 155 $12K
90651 <1% 229 $10K
86901 <1% 849 $10K
87086 Culture, bacterial; quantitative colony count, urine <1% 1,858 $9K
84450 <1% 1,767 $9K
86900 <1% 849 $9K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 975 $9K
84702 <1% 1,175 $9K
82728 <1% 601 $9K
73030 <1% 370 $8K
71250 <1% 44 $8K
85610 <1% 1,373 $8K
76642 <1% 183 $8K
83880 <1% 253 $8K
81003 <1% 4,063 $7K
82565 <1% 1,022 $7K
73130 <1% 349 $7K
90675 <1% 43 $7K
84466 <1% 844 $7K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 202 $7K
87081 <1% 1,392 $7K
82570 <1% 907 $6K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 43 $6K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 221 $6K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 4,185 $6K
76801 <1% 79 $6K
86803 <1% 473 $6K
83540 <1% 1,039 $6K
82043 <1% 801 $6K
82247 <1% 1,502 $5K
83605 <1% 1,417 $5K
86618 <1% 658 $5K
80076 <1% 227 $5K
86140 <1% 917 $5K
73110 <1% 302 $5K
90734 <1% 211 $5K
87077 <1% 693 $5K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 32 $4K
82040 <1% 1,418 $4K
84153 <1% 386 $4K
84520 <1% 579 $4K
86580 <1% 162 $4K
90656 <1% 202 $3K
85652 <1% 959 $3K
84155 <1% 1,130 $3K
90670 <1% 107 $3K
84480 <1% 303 $3K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,398 $3K
97161 <1% 25 $3K
76770 <1% 14 $3K
90732 <1% 57 $3K
0064A <1% 85 $3K
93971 <1% 26 $3K
90677 <1% 35 $3K
0001A <1% 70 $2K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 531 $2K
0002A <1% 69 $2K
94060 <1% 13 $2K
87186 <1% 535 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 4,168 $2K
72110 <1% 63 $2K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 77 $2K
82746 <1% 150 $2K
85379 <1% 258 $2K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 175 $2K
82948 <1% 1,368 $2K
87070 <1% 357 $2K
0004A <1% 43 $2K
83655 <1% 129 $1K
G0442 Annual alcohol misuse screening, 5 to 15 minutes <1% 84 $1K
87468 <1% 52 $1K
99442 <1% 13 $1K
82947 <1% 273 $1K
76536 <1% 15 $1K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 76 $1K
J7120 Ringers lactate infusion, up to 1000 cc <1% 1,068 $1K
J2704 Injection, propofol, 10 mg <1% 956 $1K
91322 <1% 29 $1K
90619 <1% 40 $1K
82550 <1% 161 $915.16
87469 <1% 52 $883.80
87484 <1% 52 $883.80
87478 <1% 52 $883.80
87040 <1% 125 $861.96
80306 <1% 142 $856.77
77066 Tomosynthesis, mammo <1% 12 $776.29
84460 <1% 69 $774.99
96376 <1% 152 $765.47
86666 <1% 171 $675.82
85730 <1% 151 $672.08
82150 <1% 113 $644.36
90472 Immunization administration, each additional vaccine (list separately) <1% 324 $621.42
94729 <1% 17 $550.39
0124A <1% 15 $540.45
97014 <1% 25 $512.38
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 2,841 $501.12
90700 <1% 27 $481.95
87476 <1% 26 $434.26
83550 <1% 146 $410.98
90480 <1% 28 $302.07
87481 <1% 12 $290.07
90633 <1% 14 $249.90
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 12 $232.08
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 2,289 $229.96
90710 <1% 12 $214.20
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 978 $196.72
87807 <1% 29 $191.75
86780 <1% 13 $171.95
86617 <1% 26 $159.88
83520 <1% 69 $154.14
73140 <1% 13 $141.96
73080 <1% 12 $115.56
86753 <1% 38 $100.16
J2270 Injection, morphine sulfate, up to 10 mg <1% 207 $96.17
82803 <1% 13 $71.52
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 69 $67.11
86038 <1% 12 $50.46
J3010 Injection, fentanyl citrate, 0.1 mg <1% 234 $41.42
86308 <1% 12 $29.71
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 642 $29.38
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 37 $11.25
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 122 $10.44
80326 <1% 14 $10.00
80364 <1% 14 $10.00
80347 <1% 14 $10.00
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 72 $7.03
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 13 $2.66
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 14 $0.39
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program <1% 23 $0.01
81513 0% 12 $0.00
96127 0% 56 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVIELKIND, JAMES (CHIEF FINANCIAL OFFICER)
Same official

Other billing entities under VIELKIND, JAMES

Full network →
ProviderLocationPaid
Little Falls HospitalLittle Falls, NY$7K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.